Literature DB >> 9174173

Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model.

S Keil1, B Wiedemann.   

Abstract

In an in vitro dynamic model we compared the antimicrobial effects of two carbapenems, imipenem (MIC, 1 microg/ml) and meropenem (MIC, 0.25 microg/ml) on Pseudomonas aeruginosa. The antibiotics were administered either as short-time infusions once or three times a day or as continuous infusions with steady-state levels ranging from 0.5 to 20 microg/ml. From the resulting kill curves the period of time until the onset of bacterial death (dt), the rate constant of bacterial death (ka), the maximal reduction of CFU (mr), and the period of time until bacterial regrowth occurred (tr) were determined. Additionally, the occurrence of bacterial resistance during the simulations (rq) and the postantibiotic effect (PAE) were recorded. For both investigated carbapenems no significant difference in dt, ka, mr, and PAE values between the short-time infusions and continuous infusions with steady-state levels above 2 microg/ml could be detected. The tr was longest with continuous infusions of over approximately 24 h, corresponding to steady-state levels of 3 microg/ml for imipenem and 2.5 microg/ml for meropenem. An increase in MIC was observed only during continuous infusions with steady-state levels below 2 microg/ml. Independent of the chosen method of application and despite the lower MIC of meropenem, imipenem was slightly more effective than meropenem.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9174173      PMCID: PMC163889          DOI: 10.1128/AAC.41.6.1215

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Pharmacokinetics of meropenem in subjects with various degrees of renal impairment.

Authors:  B A Christensson; I Nilsson-Ehle; M Hutchison; S J Haworth; B Oqvist; S R Norrby
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

Review 2.  Continuous infusion of beta-lactam antibiotics.

Authors:  W A Craig; S C Ebert
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

3.  Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models.

Authors:  S Keil; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

4.  Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.

Authors:  J W Mouton; J G den Hollander
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

5.  Multiple-dose pharmacokinetics of imipenem-cilastatin.

Authors:  G L Drusano; H C Standiford; C Bustamante; A Forrest; G Rivera; J Leslie; B Tatem; D Delaportas; R R MacGregor; S C Schimpff
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

6.  Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia.

Authors:  S Daenen; Z Erjavec; D R Uges; H G De Vries-Hospers; P De Jonge; M R Halie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

7.  Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem.

Authors:  I Odenholt-Tornqvist
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

8.  Efficacy of continuous versus intermittent administration of penicillin G in Streptococcus pneumoniae pneumonia in normal and immunodeficient rats.

Authors:  I A Bakker-Woudenberg; J C van den Berg; P Fontijne; M F Michel
Journal:  Eur J Clin Microbiol       Date:  1984-04       Impact factor: 3.267

9.  Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration.

Authors:  S A Signs; J S Tan; S J Salstrom; T M File
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

10.  Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin.

Authors:  D Paradis; F Vallée; S Allard; C Bisson; N Daviau; C Drapeau; F Auger; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

View more
  8 in total

Review 1.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

2.  Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation.

Authors:  Ben M Lomaestro; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 3.  Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.

Authors:  Mordechai Grupper; Joseph L Kuti; David P Nicolau
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

Review 4.  Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.

Authors:  Jason A Roberts; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.

Authors:  Rajbharan Yadav; Phillip J Bergen; Kate E Rogers; Carl M J Kirkpatrick; Steven C Wallis; Yuling Huang; Jürgen B Bulitta; David L Paterson; Jeffrey Lipman; Roger L Nation; Jason A Roberts; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

6.  Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration.

Authors:  F Thalhammer; P Schenk; H Burgmann; I El Menyawi; U M Hollenstein; A R Rosenkranz; G Sunder-Plassmann; S Breyer; K Ratheiser
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 7.  Continuous infusion of beta-lactam antibiotics.

Authors:  A P MacGowan; K E Bowker
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

8.  An investigation of the stability of meropenem in elastomeric infusion devices.

Authors:  Finbarr Foy; Giuseppe Luna; Jorge Martinez; Zach Nizich; Jason Seet; Katie Lie; Bruce Sunderland; Petra Czarniak
Journal:  Drug Des Devel Ther       Date:  2019-08-01       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.